Anticoagulants: To bleed or not to bleed, that is the question

Seminars in Vascular Surgery

Volumn 15, Issue 4, 2002, Pages 256-267

  Da Silva, Monica S ^a,b   Sobel, Michael ^a,b,c  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VA Puget Sound   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACOVA; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; COUMARIN DERIVATIVE; DANAPAROID; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HEPARIN DERIVATIVE; HIRUDIN; HIRUDIN DERIVATIVE; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENCY; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SKIN NECROSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT INDICATION;

EID: 0036913951     PISSN: 08957967     EISSN: None     Source Type: Journal    
DOI: 10.1053/svas.2002.36261     Document Type: Review

References (56)

1. Hyers TM, Agnelli G, Hull RD, et al: Antithrombotic therapy for venous thromboembolic disease. Chest 119:176S-193S, 2001 (suppl)
2. Hirsh J, Warkentin TE, Shaughnessy SG, et al: Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 119:64S-94S, 2001 (suppl)
3. Rosenberg RD, Bauer KA: The heparin-antithrombin system: A natural anticoagulant mechanism, in Colman RW, Hirsh J, Marder VJ, et al (eds): Hemostasis and Thrombosis: Basic Principles and Clinical Practice (Ed3). Philadelphia, PA, JB Lippincott, 1994, pp 837-860
4. Young E, Prins MH, Levine MN, et al: Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 67:639-643, 1992
5. Hirsh J, van Aken WG, Gallus AS, et al: Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 53:691-695, 1976
6. Sobel M, Fish W, Toma N, et al: Heparin modulates integrin function in human platelets. J Vasc Surg 33:587-594, 2001
7. Eika C: Inhibition of thrombin-induced aggregation of human platelets by heparin and antithrombin III. Scand J Hematol 8:250-256, 1971
8. Sobel M, McNeill PM, Carlson PL, et al: Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 87:1787-1793, 1991
9. Muir JM, Andrew M, Hirsh J, et al: Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 88:1314-1320, 1996
10. Levine MN, Raskob G, Landefeld S, et al: Hemorrhagic complications of anticoagulant treatment. Chest 119:108S-121S, 2001
11. Hobbhahn J, Conzen PF, Habazettl H, et al: Heparin reversal by protamine in humans - Complement, prostaglandins, blood cells, and hemodynamics. J Appl Physiol 71:1415-1421, 1991
12. Horrow JC: Protamine: A review of its toxicity. Anesth Analg 64:348-361, 1985
13. Messmore HL, Griffin B, Koza M, et al: Interaction of heparinoids with platelets: Comparison with heparin and low molecular weight heparins. Semin Thrombosi Hemostas 17:57-59, 1991 (suppl)
14. Laposata M, Green D, Van Cott EM, et al: The clinical use and laboratory monitoring of low-molecular-weight-heparin, danaparoid, hirudin and related compounds, and argatroban: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. Arch Pathol Lab Med 122:799-807, 1998
15. Walenga JM, Jeske WP, Samama MM, et al: Fondaparinux: A synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opinion on Investigational Drugs 11:397-407, 2002
16. Rosenberg RD: Redesigning heparin. N Engl J Med 344:673-675, 2001
17. Chong BH: Danaparoid for the treatment of heparin induced thrombocytopenia, in Warkentin TE, Greinacher A (eds): Heparin-Induced Thrombocytopenia. New York, NY, Marcel Dekker, 2000, pp 291-311
18. Newman PM, Swanson RL, Chong BH: Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 80:292-297, 1998
19. Chong BH, Gallus AS, Cade JF, et al: The Australian HIT Study Group. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: A clinical outcome. Thombosis & Haemostasis 86:1170-1175, 2001
20. Adams HP, Bendixen BH, Leira E, et al: Antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery: A report of the trial of Org 10172 in Acute Stroke Treatment. Neurology 53:122-125, 1999
21. Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators: Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial. JAMA 279:1265-1272, 1998
22. Weitz JI, Hirsh J: New anticoagulant drugs. Chest 119: 95-107, 2001
23. The OASIS-2 Investigators: The effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: A randomized trial. Lancet 353:429-438, 1998
24. Nand S: Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis. Am J Hematol 43: 310-311, 1993
25. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al: A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 337:1329-1335, 1996
26. The Direct Thrombin Inhibitor Trialists' Collaborative Group: Direct thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patients' data. Lancet 359:294-302, 2002
27. Carswell CI, Plosker GL: Bivalirudin: A review of its potential place in the management of acute coronary syndromes. Drugs 62:841-870, 2002
28. Antman EM, McCabe CH, Braunwald E: Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: Observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. Am Heart J 143:229-234, 2002
29. Greinacher A, Volpel H, Janssens U, et al: for the HIT Investigators Group: Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 99:73-80, 1999
30. Song X, Huhle G, Wang L, et al: Generation of antihirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 100:1528-1532, 1999
31. Lewis BE, Wallis DE, Berkowtiz SD, et al: ARG-911 Study Investigators: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103: 1838-1843, 2001
32. Hirsh J, Dalen JE, Anderson DR, et al: Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119:8S-21S, 2001
33. Ansell J, Hirsh J, Dalen J, et al: Managing oral anticoagulation therapy. Chest 119:22S-38S, 2001
34. Green RM, DeWeese JA, Rob CG: Arterial embolectomy before and after the Fogarty catheter. Surgery 77:24-33, 1975
35. Holm J, Schersten T: Anticoagulant treatment during and after embolectomy. Acta Chir Scand 138:683-687, 1972
36. Elliot JP, Hageman JH, Szilagyi DE, et al: Arterial embolization: Problems of source, multiplicity, recurrence, and delayed treatment. Surgery 88:833-845, 1980
37. Brown G, Dodek P: An evaluation of empiric vs nonogram-based dosing of heparin in an intensive care unit. Crit Care Med 25:1534-1538, 1997
38. Raschke RA, Reilly BM, Guidry JR, et al: The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 119:874-881, 1993
39. Hollingsworth JA, Rowe BH, Brisebois FJ, et al: The successful application of a heparin nomogram in a community Hospital. Arch Intern Med 155:2095-2100, 1995
40. Sobel M, Sternberg WC, Marques D, et al: A comparative study of heparin responses in arterial and venous thromboembolism using molecular markers for thrombosis. Circulation 88: 11426-11431, 1993
41. Hochman JS, Wall AU, Gavrila D, et al: A new regimen for heparin use in acute coronary syndromes. Am Heart J 138:313-318, 1999
42. Thompson JF, Mullee MA, Bell PRF, et al: Intraoperative heparinisation, blood loss and myocardial infarction during aortic aneurysm surgery: A Joint Vascular Research Group Study. Eur J Vasc Endovasc Surg 12:86-90, 1996
43. Jackson MR, Clagett GP: Antithrombotic therapy in peripheral arterial occlusive disease. Chest 119:283S-299S, 2001 (Suppl)
44. Mulry CC, Le Veen RF, Sobel M, et al: Assessment of heparin anticoagulation during peripheral angioplasty. J Vasc Interv Radiol 2:133-139, 1991
45. Edmondson RA, Cohen AT, Das SK, et al: Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 344:914-918, 1994
46. Sarac TP, Huber TS, Back MR, et al: Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 28:446-457, 1998
47. Johnson WC, Williford WO: Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: A prospective randomized study. J Vasc Surg 35: 413-421, 2002
48. Kretschmer G, Wenzl E, Piza F, et al: The influence of anticoagulant treatment on the probability of function in femoropopliteal vein bypass surgery: Analysis of a clinical series (1970 to 1985) and interim evaluation of a controlled clinical trial. Surgery 102:453-459, 1987
49. Kretschmer G, Herbst F, Prager M, et al: A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg 127:1112-1115, 1992
50. Kretschmer G, Schemper M, Ehringer H, et al: Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery. Lancet 1:797-799, 1988
51. Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group: Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): Randomized trial. Lancet 355:346-351, 2000
52. Albers GW, Amarenco P, Easton DJ, et al: Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 119: 300S-320S, 2001
53. Mohr JP, Thompson JLP, Lazar RM, et al: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345:1444-1451, 2001
54. Albers GW, Dalen JE, Laupacis A, et al: Antithrombotic therapy in atrial fibrillation. Chest 119:194S-206S, 2001
55. Stein PD, Alpert JS, Bussey HI, et al: Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 119: 220S-227S, 2001
56. Kearon C, Hirsh J: Current concepts: Management of anticoagulation before and after elective surgery. N Engl J Med 336:1506-1511, 1997